Semaglutide Preserves Muscle Mass and Metabolic Rate Better Than Dieting Alone in Obese Minipigs
Semaglutide mitigated the loss of fat-free mass and energy expenditure decline seen with calorie restriction alone in an obese minipig model.
Quick Facts
What This Study Found
Semaglutide treatment preserved fat-free mass and energy expenditure compared to diet restriction alone in obese minipigs, demonstrating more favorable body composition changes.
Key Numbers
How They Did This
Controlled study in diet-induced obese Göttingen minipigs (n=8/group): control (ad libitum), semaglutide-treated, and diet-restricted groups, measuring body composition and energy expenditure.
Why This Research Matters
Critics worry GLP-1 drugs cause excessive muscle loss. This data suggests semaglutide actually preserves muscle better than equivalent calorie restriction, addressing a key safety concern.
The Bigger Picture
This challenges the narrative that GLP-1 drugs cause harmful muscle loss, suggesting the body composition profile of pharmacological weight loss may be superior to dieting.
What This Study Doesn't Tell Us
Minipig model — not human data. Small group sizes (n=8). Short study duration may not capture long-term body composition changes.
Questions This Raises
- ?Do human studies confirm that semaglutide preserves muscle mass compared to dieting?
- ?Does preserved muscle mass translate to better functional outcomes?
Trust & Context
- Key Stat:
- Muscle + metabolism preserved Semaglutide maintained fat-free mass and energy expenditure vs diet restriction alone
- Evidence Grade:
- Preclinical animal study using a translational obesity model — provides valuable mechanistic data but needs human confirmation.
- Study Age:
- Published in 2026; uses the Göttingen minipig, considered one of the best large animal models for human obesity.
- Original Title:
- Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.
- Published In:
- American journal of physiology. Endocrinology and metabolism (2026)
- Authors:
- Bredum, Simon Krogh, Jacobsen, Julie M, Halling, Jens Frey, Blom, Ida, Lewis, Christopher T A, Ochala, Julien, Fredholm, Merete, Lundh, Sofia, Schmücker, Malte, Ozenne, Brice, Domingos, Ana I, Hald, Bjørn Olav, Larsen, Steen, Cirera, Susanna, Christoffersen, Berit Oestergaard
- Database ID:
- RPEP-14906
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide cause muscle loss?
This minipig study actually shows semaglutide preserves more muscle mass than equivalent calorie restriction. Some muscle loss occurs with any weight loss, but semaglutide may produce a better ratio of fat to muscle loss.
Why use minipigs for this research?
Göttingen minipigs closely mimic human obesity in body fat distribution, metabolism, and response to weight loss treatments, making them one of the best animal models for obesity research.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14906APA
Bredum, Simon Krogh; Jacobsen, Julie M; Halling, Jens Frey; Blom, Ida; Lewis, Christopher T A; Ochala, Julien; Fredholm, Merete; Lundh, Sofia; Schmücker, Malte; Ozenne, Brice; Domingos, Ana I; Hald, Bjørn Olav; Larsen, Steen; Cirera, Susanna; Christoffersen, Berit Oestergaard. (2026). Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.. American journal of physiology. Endocrinology and metabolism. https://doi.org/10.1152/ajpendo.00480.2024
MLA
Bredum, Simon Krogh, et al. "Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.." American journal of physiology. Endocrinology and metabolism, 2026. https://doi.org/10.1152/ajpendo.00480.2024
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide mitigates the loss of fat-free mass and decrease..." RPEP-14906. Retrieved from https://rethinkpeptides.com/research/bredum-2026-semaglutide-mitigates-the-loss
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.